Sep 25, 2026.
The IN-ARMOR project has achieved another important milestone in the preclinical development of its host-directed therapeutic approach against antimicrobial resistance (AMR).
Within Work Package 4 (WP4), led by LEITAT, the consortium has completed an important stage of the in vivo tolerability assessment of its selected immunomodulatory candidates.
The studies carried out by LEITAT in collaboration with WP4 partners, have provided essential information on the safety and tolerability of the compounds in vivo. This work is a key prerequisite for planning subsequent preclinical studies and for establishing appropriate conditions for evaluating the therapeutic potential of the candidates.
Safety assessment is a critical component of the IN-ARMOR development pathway. Before potential new therapies can progress towards more advanced stages of research, their safety profile needs to be carefully investigated through a stepwise preclinical evaluation.
Supporting the next stage of research
The completion of this milestone provides the consortium with valuable information to guide the design of subsequent efficacy studies in relevant disease models.
Together with the results generated through the project’s in vitro characterisation and nanodelivery activities, these findings contribute to building the evidence base required to advance the most promising candidates through the IN-ARMOR preclinical pipeline.
This achievement marks another step towards the project’s broader objective: developing innovative host-directed therapies that harness and strengthen the body’s innate immune defences as a complementary approach to tackling antimicrobial-resistant infections.
